Molecular Partners shares surge 13.53% after-hours after announcing three AACR 2026 poster presentations on Switch-DARPin and Radio-DARPin platforms.

Molecular Partners surged 13.53% in after-hours trading following the announcement of three poster presentations at the AACR 2026 Annual Meeting, showcasing advancements in its Switch-DARPin and Radio-DARPin platforms. The posters highlighted tumor-localized immune activation, computational workflows for immunotherapy development, and a clinical-stage radiotherapeutic candidate for small cell lung cancer. These updates underscored the company’s progress in addressing oncology challenges through innovative protein therapeutics, potentially enhancing investor confidence in its pipeline. The timing aligns with the April 17–22 conference, positioning Molecular Partners to generate scientific and market interest in its next-generation cancer treatments.